000279196 001__ 279196
000279196 005__ 20250709100937.0
000279196 0247_ $$2doi$$a10.3390/jcm14113769
000279196 0247_ $$2pmid$$apmid:40507531
000279196 0247_ $$2pmc$$apmc:PMC12156941
000279196 037__ $$aDZNE-2025-00724
000279196 041__ $$aEnglish
000279196 082__ $$a610
000279196 1001_ $$0P:(DE-2719)9001510$$aGrobe-Einsler, Marcus$$b0$$eFirst author$$udzne
000279196 245__ $$aFeasibility of an App-Assisted and Home-Based Video Version of the Timed Up and Go Test for Patients with Parkinson Disease: vTUG.
000279196 260__ $$aBasel$$bMDPI$$c2025
000279196 3367_ $$2DRIVER$$aarticle
000279196 3367_ $$2DataCite$$aOutput Types/Journal article
000279196 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1751974579_26500
000279196 3367_ $$2BibTeX$$aARTICLE
000279196 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000279196 3367_ $$00$$2EndNote$$aJournal Article
000279196 520__ $$aBackground: Parkinson Disease (PD) is a progressive neurodegenerative disorder. Current therapeutic trials investigate treatments that can potentially modify the disease course. Testing their efficiency requires outcome assessments that are relevant to patients' daily lives, which include gait and balance. Home-based examinations may enhance patient compliance and, in addition, produce more reliable results by assessing patients more regularly in their familiar surroundings. Objective: The objective of this pilot study was to assess the feasibility of a home-based outcome assessment designed to video record the Timed up and Go (vTUG) test via a study-specific smartphone app for patients with PD. Methods: 28 patients were recruited and asked to perform at home each week a set of three consecutive vTUG tests, over a period of 12 weeks using an app. The videos were subjected to a manual review to ascertain the durations of the individual vTUG phases, as well as to identify any errors or deviations in the setup that might have influenced the result. To evaluate the usability and user-friendliness of the vTUG and app, the System Usability Scale (SUS) and User Experience Questionnaire (UEQ) were administered to patients at the study end. Results: 19 patients completed the 12-week study, 17 of which recorded 10 videos or more. A total of 706 vTUGs with complete timings were recorded. Random Forest Regression yielded 'time to walk up' as the most important segment of the vTUG for predicting the total time. Variance of vTUG total time was significantly higher between weeks than it was between the three consecutive vTUGs at one time point [F(254,23) = 6.50, p < 0.001]. The correlation between vTUG total time and UPDRS III total score was weak (r = 0.24). The correlation between vTUG and a derived gait subscore (UPDRS III items 9-13) was moderate (r = 0.59). A linear mixed-effects model revealed a significant effect of patient-reported motion status on vTUG total time. Including additional variables such as UPDRS III gait subscore, footwear and chairs used further improved the model fit. Conclusions: Assessment of gait and balance by home-based vTUG is feasible. Factors influencing the read-out were identified and could be better controlled for future use and longitudinal trials.
000279196 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000279196 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000279196 650_7 $$2Other$$adigital biomarkers
000279196 650_7 $$2Other$$ahome monitoring
000279196 650_7 $$2Other$$amotor assessments
000279196 7001_ $$aGerdes, Anna$$b1
000279196 7001_ $$0P:(DE-2719)9000884$$aFeige, Tim$$b2
000279196 7001_ $$0P:(DE-2719)9002174$$aMaas, Vivian$$b3$$udzne
000279196 7001_ $$00000-0001-6994-3945$$aMatthews, Clare$$b4
000279196 7001_ $$aMendoza García, Alejandro$$b5
000279196 7001_ $$aComas Fages, Laia$$b6
000279196 7001_ $$aHaf Davies, Elin$$b7
000279196 7001_ $$0P:(DE-2719)2810314$$aKlockgether, Thomas$$b8$$udzne
000279196 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn H$$b9$$eLast author
000279196 770__ $$aDigital Health Technologies in Parkinson’s Disease and Related Disorders
000279196 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm14113769$$gVol. 14, no. 11, p. 3769 -$$n11$$p3769$$tJournal of Clinical Medicine$$v14$$x2077-0383$$y2025
000279196 8564_ $$uhttps://pub.dzne.de/record/279196/files/DZNE-2025-00724.pdf$$yOpenAccess
000279196 8564_ $$uhttps://pub.dzne.de/record/279196/files/DZNE-2025-00724.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000279196 909CO $$ooai:pub.dzne.de:279196$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000279196 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001510$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279196 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000884$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000279196 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002174$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000279196 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810314$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000279196 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000279196 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000279196 9141_ $$y2025
000279196 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000279196 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000279196 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2022$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000279196 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000279196 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000279196 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000279196 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x1
000279196 9201_ $$0I:(DE-2719)1011401$$kClinical Research Platform (CRP)$$lClinical Research Platform (CRP)$$x2
000279196 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x3
000279196 980__ $$ajournal
000279196 980__ $$aVDB
000279196 980__ $$aUNRESTRICTED
000279196 980__ $$aI:(DE-2719)1710012
000279196 980__ $$aI:(DE-2719)1011001
000279196 980__ $$aI:(DE-2719)1011401
000279196 980__ $$aI:(DE-2719)1011101
000279196 9801_ $$aFullTexts